What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Chemotherapy
Gautam Borthakur focuses on Internal medicine, Myeloid leukemia, Leukemia, Surgery and Oncology.
His work deals with themes such as Gastroenterology and Immunology, which intersect with Internal medicine.
His Myeloid leukemia study is concerned with the field of Cancer research as a whole.
His biological study spans a wide range of topics, including Myeloid, Pharmacology and Performance status.
His Surgery study combines topics in areas such as Azacitidine and Midostaurin.
His work carried out in the field of Oncology brings together such families of science as Survival analysis, Pediatrics and Decitabine.
His most cited work include:
- Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia (359 citations)
- Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia (303 citations)
- Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera (294 citations)
What are the main themes of his work throughout his whole career to date?
Internal medicine, Oncology, Myeloid leukemia, Gastroenterology and Surgery are his primary areas of study.
Much of his study explores Internal medicine relationship to Decitabine.
The various areas that Gautam Borthakur examines in his Oncology study include Myelodysplastic syndromes, Cancer, Chemotherapy and Immunology.
His Myeloid leukemia research incorporates themes from Myeloid, Tyrosine kinase, Refractory and Bone marrow.
His studies deal with areas such as Vincristine, Anemia, Toxicity, Acute lymphocytic leukemia and Performance status as well as Gastroenterology.
His Leukemia research is multidisciplinary, incorporating perspectives in Clinical trial and Pharmacology.
He most often published in these fields:
- Internal medicine (77.57%)
- Oncology (37.10%)
- Myeloid leukemia (36.26%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (77.57%)
- Myeloid leukemia (36.26%)
- Oncology (37.10%)
In recent papers he was focusing on the following fields of study:
Gautam Borthakur spends much of his time researching Internal medicine, Myeloid leukemia, Oncology, Cancer research and Venetoclax.
His studies in Internal medicine integrate themes in fields like Gastroenterology and Decitabine.
His Myeloid leukemia research is multidisciplinary, relying on both Myeloid, Adverse effect, Leukemia, Bone marrow and Cohort.
Gautam Borthakur interconnects Azacitidine, Newly diagnosed, Cancer and Refractory in the investigation of issues within Oncology.
He combines subjects such as Relapsed refractory, Tyrosine kinase, Mutant and Apoptosis with his study of Cancer research.
Gautam Borthakur has researched Venetoclax in several fields, including Neutropenia and Combination therapy.
Between 2018 and 2021, his most popular works were:
- Ibrutinib and venetoclax for first-line treatment of CLL (160 citations)
- Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality (59 citations)
- Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms (48 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Chemotherapy
Gautam Borthakur mostly deals with Internal medicine, Myeloid leukemia, Oncology, Venetoclax and Leukemia.
His research combines Gastroenterology and Internal medicine.
The concepts of his Myeloid leukemia study are interwoven with issues in Tyrosine-kinase inhibitor, Drug resistance, Cohort and Intensive care medicine.
Gautam Borthakur has included themes like Blinatumomab, Philadelphia Chromosome Negative, Hypomethylating agent and Chemotherapy in his Oncology study.
His Venetoclax research incorporates elements of Chemotherapy regimen, Combination therapy and Decitabine.
The study incorporates disciplines such as Cancer, Myeloid, Akt Inhibitor GSK2141795, Trametinib and PTEN in addition to Leukemia.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
